Collaborative and Other Relationships Textual (Details)					1 Months Ended		12 Months Ended
	Nov. 03, 2023 USD ($) payment	Sep. 15, 2021 USD ($)	Nov. 05, 2019 USD ($)	Sep. 30, 2013 USD ($)	Aug. 31, 2020 USD ($)	Sep. 30, 2018 USD ($) dose	Dec. 31, 2022 USD ($) dose	Dec. 31, 2021 USD ($) dose	Dec. 31, 2019 USD ($) dose	Nov. 30, 2023	Mar. 31, 2015 USD ($)
U.S. Department of Health and Human Services, net
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Collaborative agreement contract value						$ 34,660,000
Contract term (year)						5 years
U.S. Department of Health and Human Services, net | RAPIVAB
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of products, doses | dose						50,000
Number of product delivered, doses | dose							49,980		20,000
Proceeds from collaborators							$ 13,864,000	$ 6,918,000	$ 13,864,000
Number of additional products, doses | dose							20,000	9,980
Torii Pharmaceutical Co
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Contract with customer, liability			$ 22,000,000
Potential milestone payments receivable if regulatory approval before december 31, 2021			$ 15,000,000
Maximum customary reduction on royalty rate			50.00%
Royalty payments receivable, expiration term from first commercial (year)			10 years
Torii Pharmaceutical Co | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Royalty rate if maintains sakigake designation			20.00%							20.00%
Torii Pharmaceutical Co | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Royalty rate if maintains sakigake designation			40.00%							80.00%
Clearside Biomedical, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
License agreement, upfront payment	$ 5,000,000
Number of milestone payments | payment	3
Royalty payment, number of tiers | payment	3
Clearside Biomedical, Inc. | Annual Net Sales Of $2 Million
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual global net sales	$ 2,000,000,000
Clearside Biomedical, Inc. | Annual Net Sales Greater Than $1.5 Million
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual global net sales	1,500,000,000
Clearside Biomedical, Inc. | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Potential milestone payments payable	30,000,000
Potential milestone payments payable if regulatory approval before milestone	$ 47,500,000
Base Contract
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Government contract receivable											$ 16,265,000
Additional Development Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Government contract receivable											22,855,000
ASPRBARDA Contract
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Government contract receivable											$ 39,120,000
Proceeds from awards for research and development contracts							$ 20,574,000
National Institute of Allergy and Infectious Diseases
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Receivable from awards for research and development contracts		$ 47,315,000		$ 45,931,000
Potential aggregate maximum amount of funding					$ 43,908,000
Collaborative agreement contract value					$ 6,326,000